Johnson & Johnson’s Q3 2026 Innovative Medicine segment faces a consensus revenue estimate near $16.59–16.7 billion, with operational growth projected around 6–7% year-over-year. Primary drivers include strong contributions from Darzalex (oncology), Tremfya and newer immunology launches such as Icotyde, plus Carvykti, Tecvayli, Rybrevant, Spravato, and Caplyta, which are expected to more than offset the steep Stelara decline following loss of exclusivity. MedTech softness and acquisition-related costs may pressure adjusted EPS relative to revenue, while the company’s recent full-year guidance raise to a $101.1–101.2 billion sales midpoint reflects sustained portfolio momentum. Traders will focus on whether new-product uptake sustains the segment above the $16.6 billion threshold amid these offsets.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour1H6H1D7D30DALL
View resolved

Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes